Showing 5521-5530 of 5956 results for "".
- ProQR: RNA Therapy Has Potential to Restore Vision in Patients With Usher Syndromehttps://modernod.com/news/proqr-rna-therapy-has-potential-to-restore-vision-in-patients-with-usher-syndrome/2479570/Usher syndrome is an inherited retinal degeneration that affects hearing, balance, and vision. Usher syndrome caused by USH2A mutations is one of the most common causes of retinitis pigmentosa (RP) with syndromic features. Currently there is no treatment for the sensory deficits caused by Usher s
- EyeSouth Establishes Presence in Alabama Through Affiliation with Montgomery Eye Physicianshttps://modernod.com/news/eyesouth-establishes-presence-in-alabama-through-affiliation-with-montgomery-eye-physicians/2476711/EyeSouth Partners has announced that it has completed an affiliation with Montgomery Eye Physicians and Prescription Eyewear. The affiliation will be EyeSouth’s first in Alabama. Terms of the deal were not disclosed. EyeSouth is an eye care-focused management services organization.
- Small Percentage of Ophthalmologists Perform Large Proportion of Intravitreal Anti-VEGF Injectionshttps://modernod.com/news/small-percentage-of-ophthalmologists-perform-large-proportion-of-intravitreal-anti-vegf-injections/2476712/Three percent of ophthalmologists perform 17% to 31% of all anti-vascular endothelial growth factor (VEGF) injections in the U.S., depending on the agent used, according to new findings, as reported by Reuters. “More important
- Nicox Signs Agreement for NCX 4251 in China with Ocumension Therapeutics for Up to €12 Millionhttps://modernod.com/news/nicox-signs-agreement-for-ncx-4251-in-china-with-ocumension-therapeutics-for-up-to-e12-million/2476710/Nicox SA and Ocumension Therapeutics announced they have entered into an exclusive license agreement for the development and commercialization of Nicox’s product candidate, NCX 4251—currently in a phase 2 trial in the United States in patients with acute exacerbations of blepharitis—for a territo
- Low-Cost Retinal Scanner Could Help Prevent Blindness Worldwidehttps://modernod.com/news/low-cost-retinal-scanner-could-help-prevent-blindness-worldwide/2476705/Biomedical engineers at Duke University have developed a low-cost, portable optical coherence tomography (OCT) scanner that promises to bring the vision-saving technology to underserved regions throughout the United States and abroad, according to a university news release. Thanks to a red
- Oxurion NV Reports Topline Phase 1 Results with THR-149 for the treatment of DMEhttps://modernod.com/news/oxurion-nv-reports-topline-phase-1-results-with-thr-149-for-the-treatment-of-dme/2476706/Oxurion NV reported positive topline data from a phase 1 study with THR-149, a novel, potent, plasma kallikrein (PKal) inhibitor for the treatment of diabetic macular edema (DME). THR-149 has been developed in partnership with Bicycle Therapeutics. Oxurion holds the exclusive license to the PKal
- BlephEx Asserts Claims of Patent Infringement and False Advertising Against Myco Industrieshttps://modernod.com/news/blephex-asserts-claims-of-patent-infringement-and-false-advertising-against-myco-industries/2476700/BlephEx, creator of the BlephEx device and eyelid cleaning procedure, announced that it has asserted claims of willful patent infringement and false advertising against Myco Industries and John R
- NuSight Medical Announces Issuance of U.S. Patent Covering the NuLids System for Treating Dry Eye Diseasehttps://modernod.com/news/nusight-medical-announces-issuance-of-u-s-patent-covering-the-nulids-system-for-treating-dry-eye-disease/2476697/NuSight Medical, a medical device company focused on the doctor directed, at-home treatment of dry eye disease, announced that the U.S. Patent Office has issued Patent No. 10,314,763, which is directed to methods related to the treatment of dry eye disease. U.S. Patent No. 10,314,763 cover
- Alan R. Morse, JD, PhD, Vision and Healthcare Services Innovator, Will Retire As President & CEO of Lighthouse Guildhttps://modernod.com/news/alan-r-morse-jd-phd-vision-and-healthcare-services-innovator-will-retire-as-president-ceo-of-lighthouse-guild/2476695/James M. Dubin, Chairman of the Board of Lighthouse Guild, announced that Alan R. Morse, JD, PhD, will be stepping down later this year as President & CEO of Lighthouse Guild after an extraordinary career of almost 52 years as a leader and innovator in the field
- PlanetVA Launches Eyewear Virtual Try-On Platform That Creates a 3D Face Model From Selfiehttps://modernod.com/news/planetva-launches-eyewear-virtual-try-on-platform-that-creates-a-3d-face-model-from-selfie/2476684/PlanetVA announced the launch of its latest eyewear virtual try-on platform: vmPRO. By just taking a selfie, the app creates a 3D face model of the user in just a matter of seconds. This app leverages current augmented reality trends and the latest artificial intelligence algorithms to allow th